Abstract
Pediatric critical asthma, or formerly known as status asthmaticus, is a common pediatric condition encountered in emergency departments, hospital wards, and pediatric intensive care units. Systemic corticosteroids and inhaled bronchodilators are evidence-based, initial treatments for patients with pediatric critical asthma. If clinical symptoms do not improve, pediatric practitioners often prescribe adjunctive medications including inhaled anticholinergics, intravenous ketamine, intravenous magnesium, intravenous short acting beta 2 agonists, and intravenous methylxanthines (such as aminophylline). In this narrative review, we will summarize the current evidence and present the research gaps related to these therapies in the pediatric population.
- Pediatrics
- Status Asthmaticus
- Critical Care
- Bronchodilator Agents
- Glucocorticoids
- Ketamine
- Magnesium
- Aminophylline
- Terbutaline
Footnotes
- Corresponding author:
Samer Abu-Sultaneh, MD, FAAP, FCCM, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, 705 Riley Hospital Drive, Riley Phase 2 Room 4900, Indianapolis, Indiana 46202–5225, 317–948-7185 Tel, 317–944-3442 Fax sultaneh{at}iu.edu
- Received August 20, 2024.
- Accepted September 26, 2024.
- Copyright © 2024 by Daedalus Enterprises